Summary We compared global levels of DNA methylation as well as methylation of a specific locus (MyoDl) in ovarian cystadenomas, ovarian tumours of low malignant potential (LMP) and ovarian carcinomas to investigate the association between changes in DNA methylation and ovarian tumour development. As we realized that cystadenomas showed different methylation patterns from both LMP tumours and carcinomas, we verified their monoclonal origin as a means of confirming their true neoplastic nature. High-pressure liquid chromatographic (HPLC) analyses showed that global methylation levels in LMP tumours and carcinomas were 21% and 25% lower than in cystadenomas respectively (P = 0.0001 by one-way variance analysis). Changes in the methylation status of the MyoDl locus were not seen in any of ten cystadenomas analysed but were present in five of ten LMP tumours and in five of ten carcinomas (P = 0.03). These findings suggest that alterations in DNA methylation are absent (or at least not as extensive) in ovarian cystadenomas, but are present in LMP tumours, the phenotypic features of which are intermediate between those of benign and malignant ovarian tumours. The results also emphasize the merit of distinguishing ovarian LMP tumours from cystadenomas, in spite of their similar clinical characteristics.
The phenotypic characteristics of every living cell are determined primarily by the nucleotide sequence of their respective genome. However, several epigenetic mechanisms may modulate genomic activity and further contribute to phenotypic variation. Methylation of the 5-position of cytosine, which is the only known covalent modification of mammalian DNA, may be an important example [see Bird (1992) for review]. This modification is essential for mammalian development because mice that have a reduced ability to methylate their DNA owing to mutations in the methyltransferase gene die early during embryogenesis (Li et al, 1992) .
Patterns of methylation are heritable, undergo characteristic changes during embryological development and are tissue specific (Bird, 1986) . Alterations in DNA methylation can be correlated with a variety of processes, including control of gene expression (Ehrlich and Wang, 1981; Keshet et al, 1985) , X-chromosomal inactivation (Mohandas et al, 1981) , chromatin structure (Antequera et al, 1990) , genomic imprinting (Li et al, 1993 ) and timing of replication (Selig et al, 1988) . Evidence is also growing that alterations in DNA methylation play a major role in the development of human cancers (Spruck et al, 1993; Laird and Jaenisch, 1994) . Indeed, changes in genomic methylation, either focal or global, are one of the most consistent findings in human cancers (Gama-Sosa et al, 1983 ; Makos et al, 1993; Vertino et al, 1993) and an epigenetic mechanism was proposed whereby such changes may contribute to neoplastic transformation by changing the expression patterns of genes involved in growth control (Antequera et al, 1990; Jones et al, 1990) . For example, hypomethylation of several proto-oncogenes including c-myc (Munzel et al, 1991; Sharrard et al, 1992) , ras (Bhave et al, 1988) , raf (Ray et al, 1994) , bcl-2 (Hanada et al, 1993) , erb-Al (Lipsanen et al, 1988) , and c-fins (Felgner et al, 1991) was reported in various types of cancerous tissues. In addition, expression of several tumour-suppressor genes including p16/CDKN2 (Merlo et al, 1995; Gonzalez-Zulueta et al, 1995; Herman et al, 1994) , retinoblastoma (Greger et al, 1989; Sakai et al, 1991) and von Hippel Lindau gene (Herman et al, 1994) can be turned off by methylation.
It is of interest to know the time point at which changes in DNA methylation occur during tumour development. This is not only important for our understanding of the molecular mechanisms underlying tumorigenesis, but is also relevant for the potential use of methylation-interfering drugs in cancer chemotherapy. This issue was raised more than a decade ago for colorectal tumours (Feinberg and Vogelstein, 1983; Goelz et al, 1985) . Global hypomethylation of benign colorectal polyps was found to be similar to that present in colorectal carcinomas in these studies, suggesting that such changes precede the appearance of the malignant phenotype and are thus involved in early steps of neoplastic transformation (Feinberg et al, 1988; Fearon and Vogelstein, 1990) . In contrast, Gama-Sosa et al (1983) studied over 100 samples from a large variety of different tumour subtypes, including benign neoplasms, and found that hypermethylation was a general feature of malignancy. More recently, Nelkin et al (1991) found methylation changes to be associated with the accelerated but not the chronic phase of chronic myelogenous leukaemia, suggesting a role for DNA methylation in the later stages of this particular tumour.
We used the ovarian model of tumour development to further examine the association between alterations in DNA methylation and specific stages of tumorigenesis. Like colorectal tumours, ovarian epithelial tumours are subdivided into benign (cystadenomas) and malignant (carcinomas) categories. In contrast to the benign colorectal tumours that are often regarded as premalignant lesions with a high tendency to progress to carcinomas, the benign ovarian lesions appear more stable and much less likely to undergo such progression. These lesions are therefore presumably more homogeneous as a result of this apparent stability. The attraction of the ovarian model is further enhanced by the fact that these tumours also include a third category, called tumours of low malignant potential (LMP), which are intermediate between cystadenomas and carcinomas and, like the benign tumours, are stable over time.
We examined and compared the levels of DNA methylation in ovarian cystadenomas, LMP tumours and carcinomas in the present manuscript. We reasoned that cystadenomas and LMP tumours could be regarded as early steps of malignant transformation and we therefore sought to determine which step, if any, was associated with DNA methylation changes. We also reasoned that these experiments could provide us with an opportunity to examine whether cystadenomas and LMP tumours are mechanistically similar or not, as the merit of classifying these two tumour subtypes into separate categories is currently the subject of much debate among pathologists (Kurman and Trimble, 1993) . The degree of global DNA methylation in ovarian cystadenomas, LMP tumours and carcinomas was compared using high-pressure liquid chromatography (HPLC). We also examined the extent of methylation of a specific gene, called MyoDl in each tumour type. The latter gene was selected for two reasons. First, changes in the patterns of methylation of MyoDl have been reported in various tumour types (Rideout et al, 1994) . We speculated that similar changes may be present in ovarian tumours. Second, in contrast to global levels of DNA methylation, which are decreased in most neoplastic tumours (Gama-Sosa et al, 1983) , MyoDl methylation is increased in some malignant tumours (Rideout et al, 1994) . We were interested to know if changes leading to such hypermethylation of specific genes occurred at the same stages of ovarian tumorigenesis as those leading to global hypomethylation. As we realized that differences in DNA methylation patterns distinguished carcinomas and LMP tumours from cystadenomas, we also sought to verify that ovarian cystadenomas are authentic neoplasms and not hyperplastic conditions in order to better understand the significance of DNA methylation differences between cystadenomas and other subtypes of ovarian epithelial tumours.
MATERIALS AND METHODS Source and processing of tissue specimens
Tumour specimens were obtained fresh from the operating rooms of either the USC/Norris Comprehensive Cancer Center or the Women's Hospital of the Los Angeles County Medical Center and frozen immediately. All tissues were obtained in compliance with the rules of the Institutional Tissue Committee at the University of Southern California and after approval was obtained from that committee. Diagnostic verification of each case was done by one of us (LD), who is a surgical pathologist familiar with ovarian tumour histopathology. Histological sections of all frozen carcinoma and LMP tumour samples were examined before DNA extraction in order to confirm the presence of tumour tissue and to rule out the presence of unacceptable amounts of non-neoplastic stroma. For cystadenomas, the inner linings of the neoplastic cysts were scraped with scalpel blades in order to separate the neoplastic cells from underlying cyst walls. Analysis of cells recovered in such scrapings by flow cytometry revealed that over 99% stained positively with anti-keratin monoclonal antibodies and were therefore of epithelial origin (not shown). DNA was extracted from each tissue sample as described previously (Zheng et al, 1995) .
High-pressure liquid-chromatography DNA samples were digested by nuclease P1 (Boehringer Mannheim, Indianapolis, IN, USA) and alkaline phosphatase (Promega, Madison, WI, USA) for 4 h at 37°C (Gehrke et al, 1984) . Samples were centrifuged, and 25-to 200-p1 aliquots of the supernatants were injected directly into a HPLC apparatus (purchased from Waters, Milford, MA, USA), equipped with a 440 Absorbance Detector and a 10 cm Brownlee RP-18 column guarded by a Brownlee Aquaphore ODS precolumn. A solution containing 50 mM sodium dihydrogen phosphate, pH 4.0 and 2.5% methanol was used as mobile phase. The flow rate was set at 1 ml min-, and the absorbance was monitored at 254 nm. Retention times were 6 min for deoxycytosine, 7.4 min for 5-methyldeoxycytosine, 9 min for deoxythymidine, 10.5 min for deoxyguanosine, and 29 min for deoxyadenosine under those conditions. The purity of each peak was verified by variations of mobile phase pH and methanol concentrations. Standard deoxynucleosides were obtained from Sigma (St Louis, MO, USA).
Southern blotting analysis
An aliquot of 10 gg of each DNA sample was digested with either the methylation-sensitive HpaII or the methylationinsensitive MspI restriction endonuclease following manufacturer's (Boehringer-Mannheim) recommendations. The digested DNA samples were electrophoresed on 1% agarose and transferred to Zetabind nylon membranes (BioRad, Richmond, CA, USA) as described previously (Ehlen and Dubeau, 1990) . The membranes were hybridized to a radiolabelled 800-base pair cDNA probe for the MyoD I locus obtained from Professor HH Arnold (Braun et al, 1994) of the University of Braunschweig (Germany), and autoradiographed. Conditions for hybridization and probe labelling were described previously (Ehlen and Dubeau, 1990 ).
Analysis of X-chromosome Inactivation
An aliquot of 1 p1 of DNA isolated from either the patient's blood or from the epithelial cells lining ovarian cysts was incubated overnight in the presence or absence of 5 units of HpaII restriction endonuclease in a total volume of 10 pl. Polymerase chain reaction (PCR) reagents were then added to each tube, bringing the final volume to 100 gl. Sense and antisense primers were 5'-TGCGCGAAGTGATCCAGAAC-3' and 5'-CTTGGGGAGAAC-CATCCTCA-3' respectively. These primers flank a trinucleotide repeat polymorphism in exon 1 of the androgen receptor gene (Sleddens et al, 1992) as well as two HpaII restriction endonuclease sites located within 100 bases of this polymorphism (Allen et al, 1992 [a-32P]dCTP (ICN Radiochemicals, Irvine, CA, USA). Primers for this reamplification reaction were: 5'-GAAGATTCAGC-CAAGCTCAA-3' and 5'-TGAAGGTTGCTGTTCCTCAT-3'. The radiolabelled products were electrophoresed on 6% polyacrylamide gels under denaturing conditions and autoradiographed.
Statistical analysis
The analysis of variance method was used to compare 5-methylcytosine levels in cystadenomas, LMP tumours and carcinomas (Dixon and Massey, 1969 ). Fisher's exact test (Dixon and Massey, 1969) was used to compare the proportions of tumours with methylation changes in the cystadenoma group vs the group of LMP tumours and carcinomas. All P-values quoted are two-sided. Figure 2 Clonal origin of ovarian cystadenomas. DNA obtained from either blood (B) or tumour (T) samples of a patient with a large serous ovarian cystadenoma was either left undigested or digested with the Hpall restriction endonuclease. Each sample was then amplified enzymatically using primers flanking a trinucleotide repeat polymorphism in the first exon of the androgen receptor gene as well as two Hpall sites located within 100 base pairs of this polymorphism. The radiolabelled PCR products were electrophoresed on 6% agarose under denaturing conditions and autoradiographed of the small number of tumours examined. However, there were no apparent associations between DNA methylation levels and either serous, mucinous, or endometrioid differentiation. We also measured 5-methylcytosine levels in four samples of normal ovarian tissues. Such levels were significantly higher than in cystadenomas (1.51 mol%, standard deviation 0.19%). The significance of these differences between normal ovarian tissues and cystadenomas, however, is unclear (see Discussion).
RESULTS

Global
Methylation of the MyoDl locus in ovarian cystadenomas, LMP tumours and carcinomas
The above results suggest that global changes in DNA methylation in ovarian epithelial tumours are most extensive in LMP tumours and carcinomas. We therefore assessed levels of methylation of the MyoDl locus in such tumours in order to determine whether methylation changes also correlate with the degree of neoplastic transformation at the level of individual genes. Interestingly, studies of MyoDl methylation in other tumour models suggested that there is increased methylation at this locus in malignant tumours (Rideout et al, 1994) , reflecting the fact that both, local hypo-and hypermethylation changes occur during tumorigenesis. We therefore sought to determine if changes affecting the MyoDl locus occur at the same stage of tumorigenesis as those responsible for generalized genomic hypomethylation. We took advantage of the fact that two potential methylation sites in the MyoD I locus are within recognition sequences for the methylation-sensitive HpaII restriction endonuclease. Methylation of these two sites has previously been associated with malignant transformation (Rideout et al, 1994) . DNA from the various tumour samples was digested either with this enzyme or with the MspI endonuclease. The latter enzyme recognizes the same sequence as HpaII but is methylation insensitive. The digested samples were electrophoresed on 1% agarose and analysed by Southern blotting using a cDNA probe for MyoD1.
The results for selected cystadenomas and LMP tumours are shown in Figure 1 . DNA digested with MspI produced a single fragment of 603 base pairs in each case. The same fragment was obtained after digestion of cystadenoma DNA with HpaII. Thus, the HpaII sites at the MyoDl locus were totally unmethylated in these tumours because the presence of methylated cytosines would have prevented cleavage by this enzyme and resulted in fragments of larger sizes. Such larger fragments were found in three of the five LMP tumours illustrated in the figure.
The above approach was used to examine the methylation status of HpaII sites in the MyoD 1 locus in five normal ovaries, ten cystadenomas, ten LMP tumours and ten carcinomas. The results are shown in Table 2 . None of the five normal ovarian tissue samples showed methylation of these sites. Likewise, DNA methylation was not detected in any of the ten cystadenomas examined. In contrast, five of the ten LMP tumours and five of the ten carcinomas showed methylation of either one or both HpaII sites (Table 2) . We compared the proportion of cystadenomas showing methylation changes with that of LMP tumours and found the difference to be statistically significant (P = 0.03).
Ovarian cystadenomas are authentic neoplasms
We examined eight ovarian cystadenomas ranging in size from 3 to 12 cm and determined whether these tumours were of monoclonal origin or not. Our intention was to better understand the significance of the distribution of alterations in DNA methylation in ovarian tumours, as it was unclear to us if ovarian cystadenomas represented neoplastic or hyperplastic lesions (see Discussion). Monoclonality is a feature of neoplasia whereas polyclonality is usually indicative of non-neoplastic disorders such as hyperplasia.
We therefore used an approach first developed by Vogelstein et al (1985) to examine the monoclonal origin of the above eight cystadenomas. This approach is based on the fact that all tumour cells within a given tumour mass show inactivation of the same allele of the X chromosome if the tumour originated from a single cell (monoclonal). In contrast, polyclonal cell populations show random inactivation of one or the other X chromosome allele. DNA from each of the above tumour samples as well as from each patient's blood was either undigested or digested with the HpaII restriction enzyme. This enzyme is methylation sensitive and therefore does not cleave DNA at methylated sites. The digested fragments were amplified enzymatically using primers flanking a trinucleotide repeat polymorphism in the androgen receptor gene on chromosome Xq (Sleddens et al, 1992) . These primers also flanked two sites for the HpaII restriction endonuclease that are adjacent to the trinucleotide repeat. At least one of these sites is unmethylated if it is located on an active allele of the X chromosome whereas both sites are invariably methylated if they are located on an inactive allele (Allen et al, 1992) . Thus, only sequences from inactive X chromosome alleles are amplifiable using the above set of primers because sequences from active alleles, which are sensitive to HpaII digestion, are cleaved during the prior digestion with this enzyme.
The results of a representative experiment are shown in Figure  2 . Undigested DNA from either blood or tumour samples showed fragments of two different sizes after enzymatic amplification with the above primers (Figure 2 ). These two fragments corresponded to the two alleles of the androgen receptor gene in this patient. Both alleles were also present in digested DNA from the patient's blood. This indicates that an equal proportion of each allele was resistant to HpaII digestion in this sample, confirming a polyclonal origin. However, only one of the two alleles could be amplified in digested tumour DNA, indicating that X inactivation affected this allele exclusively in all tumour cells from this patient. Similar results were obtained with all remaining seven cases examined (not shown). We conclude that ovarian cystadenomas are monoclonal and are therefore true neoplasms.
DISCUSSION
The time at which alterations in DNA methylation take place during tumour development is still not clear. Although such changes are clearly associated with the malignant phenotype in a large number of different tumour types (Gama-Sosa et al, 1983) , they are also found in some benign neoplasms such as colorectal polyps (Goelz et al, 1985; Feinberg et al, 1988) . Ovarian epithelial tumours are a good model to address this question because there are two well-defined subtypes of these tumours that do not fully express the malignant phenotype (Cheng et al, 1996) and can therefore be regarded as different early stages of malignant transformation. The results of our experiments clearly show that DNA methylation changes are present in both, ovarian LMP tumours and carcinomas, lending further support to the idea advanced by Goelz et al (1985) that such changes are early events in malignant transformation. However, our results also show that global alterations in genomic methylation are less extensive (and perhaps absent) in cystadenomas, which are authentic (although benign) neoplasms based on our demonstration of their monoclonal origin. Changes in methylation of the MyoDl locus, which were similar in LMP tumours and carcinomas, were likewise not detected in cystadenomas. We conclude that alterations in DNA methylation are early, but not initial events in ovarian tumorigenesis because they occur in LMP tumours, the phenotypic manifestations of which are intermediate between fully malignant and clearly benign ovarian tumours.
The above results also emphasize the merit of subdividing the non-invasive and non-metastatic subtypes of ovarian tumours into cystadenomas and LMP tumours. This issue is the subject of much debate among pathologists. Indeed, it has been argued that LMP tumours (at least those showing serous differentiation) typically behave as benign lesions clinically and should not therefore be regarded as a separate disease entity (Kurman and Trimble, 1993) .
However, our results suggest that such tumours (three of the five LMP tumours with methylation changes at the MyoD 1 locus were of serous differentiation) may develop through different genetic mechanisms from cystadenomas. This conclusion is also supported by recent data from our laboratory (Cheng et al, 1996) . The available evidence therefore supports the notion that LMP tumours are mechanistically more complex than cystadenomas and strongly argues in favour of maintaining the distinction between these two variants of ovarian epithelial tumours, in spite of the fact that they often show similar clinical behaviour.
We also observed substantial differences between levels of methylation in cystadenomas and those present in normal ovarian tissues. It is possible that these differences reflect methylation changes associated with the development of ovarian cystadenomas. However, normal ovaries are made up of a variety of different cell types including stromal cells, germ cells, follicular cells, etc. These different cell types probably show significant differences in their levels and patterns of DNA methylation because of their widely different functions and spectra of gene expression. Ovarian surface epithelial cells, which are the alleged origin of ovarian epithelial tumours, account for less than 1I% of the cell types present in normal ovarian tissue samples. Thus, we favour the explanation that the observed differences between the methylation levels of normal ovaries compared with ovarian cystadenomas are due primarily to differences in the various cell types present in those tissue samples.
A widely accepted theory stipulates that ovarian cystadenomas arise from invaginations of the ovarian surface, resulting in entrapment of the surface epithelial cells which, as they continue to proliferate, form intra-ovarian cysts. If true, the initial steps in cystadenoma development are not neoplastic and the above mechanism could be compatible with a hyperplastic phenomenon. Indeed, small (<1 cm) ovarian cysts are regarded as non-neoplastic by convention. We considered the possibility that larger cysts were also non-neoplastic because the differences in the methylation levels of cystadenomas compared to LMP tumours and carcinomas suggest fundamentally different underlying mechanisms for these tumour subtypes. We therefore determined whether cystadenomas were monoclonal or polyclonal because most neoplasms are thought to have a monoclonal origin whereas hyperplasias are thought to be polyclonal. However, our finding that ovarian cystadenomas are monoclonal provides strong support for their alleged neoplastic nature and does not support a hyperplastic origin. Thus, the clear differences in the DNA methylation levels of LMP tumours or carcinomas when compared with cystadenomas suggest that, although methylation changes are a general feature of malignant neoplasms, such changes are not essential for neoplastic transformation per se, at least in ovarian tumours.
It is not known if the above alterations in DNA methylation are causes or consequences of ovarian carcinoma and LMP tumour development. However, the fact that the expression of genes involved in growth control and tumorigenesis was reported to be altered as a result of DNA methylation changes in tumours of different histological types suggests that such alterations may indeed play an active and important role in the establishment of the malignant phenotype. Possibilities include the silencing of tumour-suppressor genes or the increased expression of protooncogenes (Balmain, 1995) . Identification of specific genetic targets for methylation changes in ovarian epithelial tumours may not only lead to a better understanding of the molecular mechanisms and determinants of their development, but may also facilitate the use and monitoring of methylation-targeting drugs in the treatment of ovarian cancer patients.
ABBREVIATIONS
LMP, low malignant potential; HPLC, high-pressure liquid chromatography.
